Wockhardt has received US FDA approval for marketing a generic version of 2 mg, 4 mg, 6 mg, 8 mg and 12 mg extended-release tablets containing ropinirole hydrochloride, which is used in the treatment of Parkinson’s disease. Ropinirole extended release tablet is the generic name for the brand Requip XL, marketed in the US by GlaxoSmithKline. Soon the company will launch the product in the US market.
Dr Habil Khorakiwala, Founder Chairman and Group CEO, Wockhardt said, “This is the sixth US FDA approval for Wockhardt in the past two weeks. Three of these have been for extended-release products. This continues to demonstrate Wockhardt’s capability in developing technologically challenging products.”
In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products has reaped the advantage of being an early entrant.
Wockhardt will be manufacturing the extended release tablets of ropinirole at its facility in Aurangabad. The technology for the tablets was developed in-house.
EP News Bureau
- Advertisement -
